International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma

Abstract

EMZL is a slow-growing tumour with an excellent long-term survival. Low-dose EBRT as monotherapy should be considered in localised OA-EMZL. Rituximab-based chemotherapy should be chosen in those patients with disseminated disease.